RESEARCH USE ONLY. Reference data for laboratory research. Not medical advice; not for human consumption.
Peptijournal
Calc
← Directory

Protocol Single compound

Tesofensine

Triple monoamine reuptake inhibitor referenced in appetite-regulation research.

Compare side by side →
Metabolic / Weight

Laboratory reference · in vitro research data

Research vial sizes
10 mg
Dosing data
Not listed — reference entry covers vial concentration only.
Storage
Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.

Reconstitution concentrations

Concentration per BAC-water volume; 10 units = 0.1 mL on a U-100 syringe.

VialBAC watermg/mLmg per 10 u
10 mg1 mL101
10 mg2 mL50.5
10 mg3 mL3.330.333

Calculate your vial

Add reminder

Enter your own schedule. Saved only on this device — never sent anywhere.

Research use only — educational reference, not medical advice. This line is added to every reminder.

Works with iPhone Calendar, Google Calendar and Outlook.

Saved only in this browser. My reminders

Inputs
mg
mL
1 mg = 1,000 mcg
mg

Draw to

—units

= — mL on a U-100 syringe

Concentration
—
Per unit
—
Doses / vial
—
Syringe
01020304050607080901000.0u
U-100 · 100 units (1 mL)2 unit per line

Research dossier · published literature summary

01

Mechanism of action

Tesofensine is a small-molecule (not peptide) triple monoamine reuptake inhibitor (dopamine, noradrenaline and serotonin), originally studied for Parkinson's and Alzheimer's disease.

02

Observed research endpoints

  • Phase 2 obesity trial (24 weeks): mean weight loss of 4.5%–10.6% across arms vs 2.0% with diet and placebo.
  • A mechanistic RCT found strong appetite-suppressing effects, a 4.6% higher night-time energy expenditure and greater 24-hour fat oxidation vs placebo.

03

Regulatory & safety context

  • Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
  • Monoamine reuptake inhibition is associated with heart-rate and blood-pressure increases, which were monitored in trials.

04

Citations

  1. Astrup A, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906–1913.2008-11Phase 2 randomized controlled trialRead paper ↗
  2. Sjödin A, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes. 2010;34(11):1634–1643.2010Randomized controlled trialRead paper ↗

Keep exploring

Where researchers source it

Listings are provided for reference — always verify the latest third-party COA before purchasing.

Medvinci Research

See site

Featured supplier · third-party tested, COA published per batch

View product View COA

Supplier B

TBD

Placeholder — details coming soon

View productView COA

Supplier C

TBD

Placeholder — details coming soon

View productView COA